Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Clinical trial flow chart and summary.
  • Fig. S2. Pre- and post-angioplasty images and assessment for the U.S. study.
  • Fig. S3. Schematic of the biomechanical configurations assumed by the TEVG.
  • Fig. S4. Time courses for quantities of interest using murine immunological parameters.
  • Fig. S5. Illustrative simulations with varying immuno-mediated matrix production profiles.
  • Fig. S6. Parametric studies for the four key inflammatory parameters.
  • Fig. S7. Ovine study design and surgical outcomes.
  • Fig. S8. Angiography, IVUS, and hemodynamic data analysis from ovine study.
  • Fig. S9. Ovine data predictions based on murine parameters alone.
  • Fig. S10. Histological and immunohistochemical analysis of the ovine neotissue over time.
  • Fig. S11. Evaluation of catheterization data from the U.S. trial using Japanese criteria for angioplasty.
  • Fig. S12. Frequency of individual imaging data in the U.S. trial.
  • Fig. S13. Case of reversible stenosis in the Japanese cohort.
  • Fig. S14. Computationally inferred mechanistic insights into the transient early TEVG stenosis.
  • Table S1. Clinical trial patient demographics.
  • Table S2. Release testing and postprocess monitoring criteria for clinical TEVG.
  • Table S3. Key methods and findings from our previous modeling-related studies of TEVGs.
  • Table S4. Values of all fixed model parameters in simulations for IVC-interposition grafts.
  • Table S5. Animal tracking.
  • Table S6. Ovine catheterization data.
  • Table S7. Values of inflammatory kinetic parameters that were varied through the simulations.
  • Table S8. Verification and validation steps.
  • References (5772)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (.zip format). Source code for computational model of TEVG growth and remodeling.
  • Data file S2 (Microsoft Excel format). Primary data.